Introduction
Radiation therapy is used in more than one-third of all cancer patients (Rubin and Siemann, 1993) . The basis of the success of radiotherapy is that ionizing radiation kills dividing cells and is therefore slightly more toxic to fast-growing cancer cells (Nias, 1998) . In addition, radiation can be selectively delivered in the tumor tissue, limiting the systemic effects. However, radiotherapy is often associated with severe side effects. To improve the effect of radiation therapy, it would be advantageous if the tumor cells could be sensitized to radiation. This would allow for a modulation of the radiation dose required to obtain tumor control and possibly limit the side effects without compromising treatment efficiency. In the ideal case, the radiosensitizer should have no intrinsic toxicity and preferentially sensitize tumor cells to radiation. Several lines of evidence indicate that ionizing radiation kills cancer cells by induction of DNA double-strand breaks (DSBs) (Tounekti et al., 2000) . Consequently, cells and animals with defects in DSB repair display increased sensitivity to ionizing radiation (Khanna and Jackson, 2001) . Therefore, one way to increase cells' sensitivity to ionizing radiation is by interfering with repair of DSBs.
DSBs introduced by ionizing radiation are predominantly repaired through a nonhomologous end-joining pathway that requires the ligase IV/Xrcc4 complex and the DNA-dependent protein kinase (DNA-PK) (Gottlieb and Jackson, 1993; Critchlow et al., 1997; Grawunder et al., 1998; Jackson, 2001; Khanna and Jackson, 2001) . DNA-PK is a serine-threonine protein kinase composed of two components. The catalytic subunit DNA-PKcs is a 460 kDa protein that shares homology in its kinase domain with members of the phosphatidylinositol 3-kinase (PI3-kinase) family of lipid kinases (Hartley et al., 1995) . The second component, Ku, is a heterodimer of 70 and 80 kDa proteins that functions as a DNA-binding subunit (Gottlieb and Jackson, 1993) . Ku binds specifically to DSBs via a preformed channel (Walker et al., 2001 ) and recruits DNA-PKcs to DNA ends (Gottlieb and Jackson, 1993; Gell and Jackson, 1999) . When the complete DNA-PK complex is assembled on DNA ends, the kinase is activated. Several lines of evidence indicate that activation occurs when the single-stranded 3 0 -and 5 0 -ends of the DSB are threaded into an enclosed channel present in DNA-PKcs (Leuther et al., 1999; Hammarsten et al., 2000; Ma˚rtensson and Hammarsten, 2002) . Phosphorylation by DNA-PK specifically regulates the activity of artemis , which is a nuclease that interacts with DNA-PKcs and is required for efficient DSB repair (Moshous et al., 2001) . It is therefore possible that the activation of DNA-PK by DSBs is required for processing of damaged DNA ends in the preparation for DSB repair.
Mice with targeted deletions of these DSB-repair genes share a common phenotype. They have a defect in DSB repair, a 2-5-fold increased sensitivity to ionizing radiation and a developmental block in V(D)J-recombination (Jackson S.P., 2001) . In addition to these defects, Ku70, Ku80 and ligase IV mutant animals also show neurological defects, premature cell senescence, growth retardation and a general susceptibility to cancer development (Gu et al., 1997; Mizuta et al., 1997; Frank et al., 1998; Gao et al., 1998; Ferguson et al., 2000) . In contrast, DNA-PKcs knockout mice have no additional defects and develop cancer only from the lymphoid tissues secondary to the V(D)J-recombination defect (Gao et al., 1998; Williams et al., 2001) . In fact, in a skin cancer induction assay, DNA-PKcs-deficient mice were resistant to cancer development due to rapid death of cells with DNA damage . This shows that DNA-PK is not required for normal cell function in mouse cells. It is therefore possible that a transient inhibition of DNA-PK during radiotherapy could be well tolerated. In addition, several reports indicate that DNA-PK is overexpressed in tumor cells resulting in resistance to treatment (Shen et al., 1997; Frit et al., 1999; Sirzen et al., 1999; Vaganay-Juery et al., 2000; Zhao et al., 2000; Xu et al., 2002) . It is therefore possible that an inhibitor of DNA-PK might selectively sensitize tumor cells to ionizing radiation. DNA-PK is therefore a relevant target for development of radiosensitizers.
Owing to the homology shared with PI3-kinases, a subset of the inhibitors to PI3-kinases also inhibits DNA-PK and the DSB-signaling kinase ATM. One member of this group, wortmannin, has been shown to inhibit DSB repair and result in a 2-5-fold sensitization of cells to ionizing radiation, at least partly through its ability to inhibit DNA-PK and ATM (Boulton et al., 1996; Rosenzweig et al., 1997; Chernikova et al., 1999; Wang et al., 2001) . A problem with the PI3-kinase inhibitors is that they induce cell cycle arrest and general toxicity because PI3-kinase activity is required for many cellular processes including growth factor signaling (Cospedal et al., 1999; Michell et al., 1999; Puglianiello et al., 2000) . Therefore, it will be important to develop DNA-PK inhibitors that have little effect on PI3-kinases.
In a first step towards construction of a specific inhibitor of DNA-PK, we screened a three-substituted indolin-2-ones library. This class of compounds has been used to develop several protein kinase inhibitors that are currently examined in clinical trials. In this library, we found SU11752, which acts as a competitor with ATP on DNA-PK. We have examined the biochemical and biological effects of SU11752. We have found that SU11752 inhibited DSB repair and sensitized a tumor cell line fivefold to ionizing radiation. These results indicate that DNA-PK was inhibited in cells. We also found that SU11752 did not affect ATM kinase activity at concentrations that inhibited DSB repair. In addition, no effects on cell cycle progression were observed, indicating that PI3-kinases were not targeted. We suggest that SU11752 may serve as a starting point for development of DNA-PK inhibitors that can be used to enhance radiation therapy.
Results
SU11752 inhibits DNA-PK by competitive inhibition for its ATP site SU11752 (Figure 1 ) was identified in a three-substituted indolin-2-one library, and found to have activity against DNA-PK with an IC 50 of 0.1370.028 mM. The effect of SU11752 was compared to the PI3-kinase inhibitor wortmannin. In accordance with published data, we found that wortmannin inhibited DNA-PK with an IC 50 of 0.10 mM (Figure 2a ) (Izzard et al., 1999) . Thus, SU11752 inhibited DNA-PK as efficiently as wortmannin. To characterize the mode of inhibition of DNA-PK, we measured DNA-PK activity at different ATP concentrations in the presence of fixed concentrations of SU11752. In a Lineweaver-Burk plot, the kinase activity curves converged to the same position on the y-axis, indicating that identical V max values could be obtained at all drug concentrations. These results indicated that SU11752 behaved as a competitive inhibitor for the ATP-site in DNA-PK (Figure 2b ).
To more directly assess the effects on ATP binding by SU11752, we made use of an antibody against wortmannin. It has previously been shown that wortmannin binds covalently to the ATP site in DNA-PKcs (Izzard et al., 1999) and that covalent wortmannin-DNA-PKcs complex can be detected in immunoblots with an antibody that specifically binds wortmannin (Stoyanova et al., 1997a; Izzard et al., 1999) . When ATP or other compounds that bind to the ATP site is mixed with wortmannin, the amount of covalent wortmannin-DNA-PKcs complexes detected by the antibody will be reduced. To validate this approach, we first mixed ATP or ADP at various concentrations with DNA-PKcs before addition of wortmannin, and monitored the formation of covalent wortmannin-DNA-PKcs complexes using the wortmannin antibody. As expected, ATP inhibited the formation of wortmannin-DNAPKcs complexes with an IC 50 that was fivefold lower compared to ADP (Figure 3a) . Thus, the wortmannin antibody assay was able to determine the relative affinities of ATP and ADP for the ATP site in DNAPKcs. Similarly, SU11752 was able to effectively inhibit the formation of wortmannin-DNA-PKcs complexes (Figure 3b ), confirming that SU11752 was a competitive inhibitor for the ATP site in DNA-PK.
Inhibition of the PI3-kinase p110g by SU11752
All currently available DNA-PK inhibitors were originally identified as PI3-kinase inhibitors. At higher concentrations, a subset of the PI3-kinase inhibitors, including wortmannin, show activity against DNA-PK, since these kinases has structural similarities in the kinase domain (Hartley et al., 1995) . Inhibition of PI3 kinases results in several unwanted effects for radiosensitizers, including cell cycle arrest (Collado et al., 2000) , decreased cellular glucose uptake (Hausdorff , 1999) and general cytotoxicity. It is therefore important to identify DNA-PK inhibitors that show little inhibition of PI3-kinases. We therefore compared the inhibition of recombinant human p110g, the catalytic subunit of a class IB PI3-kinase, by wortmannin and by SU11752 (Figure 4 ). Under conditions similar to the conditions used in the DNA-PK-assay, wortmannin inhibited p110g kinase activity with an IC 50 of 0.002 mM, close to values of p110g inhibition previously reported (Stoyanova et al., 1997b) . SU11752 was also able to inhibit the p110g kinase activity, but at 500-fold higher concentrations (IC 50 ¼ 1.10 mM). This shows that SU11752 is a relatively poor inhibitor of p110g.
SU11752 inhibits DSB repair and sensitizes cells to ionizing radiation
Cells lacking DNA-PK repair only a fraction of the DSBs introduced by X-rays (DiBiase et al., 2000) and they are hypersensitive to ionizing radiation (Taccioli et al., 1998; DiBiase et al., 2000) . Therefore, a DNA-PK inhibitor is expected to reduce DSB repair and sensitize cells to ionizing radiation. To assess the effect on DSBrepair, we used human glioblastoma cells with normal DNA-PK levels (M059K) or a matching cell line from the same patient lacking DNA-PKcs expression (M059J) . DSBs were introduced by the DSB-inducing drug calicheamicin g1. We have previously shown that calicheamicin g1-induced DSBs are recognized normally by DNA-PK (Ma˚rtens-son et al., 2003) and induce a normal DSB response in cells (Elmroth et al., 2003) (Figures 8, 9 ). Interestingly, we have also found that cells lacking DNA-PKcs are essentially unable to repair calicheamicin g1-induced DSBs ( Figure 5 , data not shown). Inhibition of DNA-PK was therefore expected to result in complete block in repair of calicheamicin g1-induced DSBs. First, cells were preincubated with SU11752 or wortmannin before induction of DSBs with calicheamicin g1. The initial DSB levels and DSB levels remaining after 4.5 h of repair at 371C were measured with the FAR assay (Elmroth et al., 2000) (Figure 5a ). At 12 mM, SU11752 inhibited DSB repair down to the level observed in DNA-PKcs-deficient cells (M059J) and cells treated with wortmannin (DiBiase et al., 2000) (Figure 5a ). This result indicated that 12 mM of SU11752 was sufficient to inhibit DNA-PK in cells.
We have also studied the effects of SU11752 on repair of DSBs induced by X-rays. However, initial experiments using X-ray-induced DSBs revealed only a modest inhibition of DSB repair by SU11752. A recent report shows that the FAR assay overestimates the number of X-ray-induced DSBs, since other types of DNA damage are converted to strand breaks during high-temperature protease treatment of chromatin (Stenerlow et al., 2003) . In agreement with this report, we observed a significant increase of X-ray-induced DSBs using protease treatment at 501C compared to low-temperature protease treatment. However, for calicheamicin g1-induced DSBs, there were no change in the level of DSBs with protease treatment temperature (data not shown), indicating that calicheamicin g1 did not introduce heat-labile sites. Using the refined lowtemperature protease treatment protocol, we found that 25 mM of SU11752 inhibited DSB repair down to the repair observed in cells lacking DNA-PKcs, and 12 mM had a partial effect (Figure 5b ).
We then investigated if treatment of cells with SU11752 would render them sensitive to ionizing radiation. Under conditions that resulted in inhibition of DSB repair, SU11752 and wortmannin sensitized the glioblastoma cells (M059K) to ionizing radiation using a colony-formation assay (Figure 6 ). In the absence of irradiation, 50 mM of SU11752 did not affect cell survival. Apparently, SU11752 was not toxic in the absence of irradiation (data not shown). At 2 Gy, 30% of untreated cells survived in the absence of drugs. Survival of cells was reduced to 7% by SU11752 and to 3% by wortmannin. This indicates that SU11752 sensitized cells a fivefold to ionizing radiation at 2 Gy. At higher doses of ionizing radiation, the sensitization was even more pronounced. Thus, SU11752 inhibited DSB-repair and increased cells' sensitivity to ionizing radiation, probably due to the inhibition of DNA-PK.
Effects of SU11752 on cell cycle progression PI3-kinases are required for signaling through several growth factor receptor pathways (Michell et al., 1999; Cospedal et al., 1999; Puglianiello et al., 2000) . Inhibition of PI3-kinases therefore results in a G1/S cell cycle block. To test if SU11752 inhibited cell cycle progression, we first synchronized human fibroblasts in G1 by contact inhibition. The cells were then plated at low density in the presence of wortmannin or different concentrations of SU11752. Cell cycle progression was monitored by FACS analysis after 24 h. The level of Sphase cells increased from 2 to 20% in the untreated cell population. As expected, in presence of wortmannin, the S-phase compartment was 7%, indicating an efficient G1 block (Figure 7 ). Cells treated with 12 mM SU11752 did not show any inhibition of cell cycle progression. At higher concentrations, the number of S-phase cells was gradually decreased and, at 50 mM SU11752, induced a similar inhibition of cell cycle progression as wortmannin. Figure 6 SU11752 sensitizes glioblastoma cells to X-rays. Confluent monolayers of the glioblastoma cell line M059K were pretreated with the drugs indicated for 2 h on ice and irradiated with 2, 6 or 12 Gy of X-rays. After irradiation, cells were incubated with drugs at 371C for 5 h before plating at low density. Colonies consisting of more than 50 cells were counted after 10 days. Error bars are from duplicate samples Inhibition of DNA-PK by SU11752 IH Ismail et al Thus, at concentrations that inhibited DSB repair (12 mM), SU11752 did not affect progression of the cell cycle.
Effects on [S/T]Q-motif phosphorylation by SU11752
DNA-PK is a member of a growing family of protein kinases that are activated by DNA damage. They share the PI3-kinase domain and phosphorylate target proteins at a common amino-acid motif (serine/threonine followed by glutamine, the [S/T]Q-motif) (Durocher and Jackson, 2001; Shiloh, 2001 ). Some of these kinases, including ATM and ATR, are inhibited by wortmannin (Banin et al., 1998; Chan et al., 2000; Hall-Jackson et al., 2000) . To assess if SU11752 is a general inhibitor to this class of kinases, we made use of an antibody that recognizes phosphorylated [S/T]Q-motifs found in ATM and ATR targets. This antibody has previously been used to characterize DNA-damage responses (Schwartz et al., 2002) . In the absence of DNA damage, two bands were visible in human cells. After the induction of DSBs, a reproducible pattern of bands appeared. The appearance of DNA-damage-inducible bands was completely inhibited by 10 mM wortmannin (Figure 8a ). At concentrations of SU11751 that resulted in DSB inhibition (12 mM), only a modest reduction was observed. However, at the highest concentration tested (50 mM), a strong reduction of the DNA-damage-inducible bands was evident. This indicated that SU11752 was able to inhibit other PI3-kinase-related kinases, but to a lesser extent compared to wortmannin. Histones were extracted and subjected to immunoblot using a phospho-specific anti-g-H2AX antibody (upper panel). The same samples were run on a separate SDS-PAGE and stained with Coomassie blue to show equal loading of histones (lower panel) In response to DSBs, the histone H2A variant H2AX is phosphorylated in nucleosomes close to the DSB (Rogakou et al., 1998 (Rogakou et al., , 1999 . H2AX has a C-terminal extension containing the [S/T]Q-motif that is phosphorylated by wortmannin-sensitive kinases (Paull et al., 2000; Burma et al., 2002) . In mouse cells, H2AX phosphorylation is mainly dependent on ATM kinase activity, since phosphorylation of H2AX is severely reduced in cells from an ATM knockout mouse (Burma et al., 2002, Ismail Hassan Ismail, data not shown) . However, in human cells lacking the ATM kinase (ATcells), H2AX was phosphorylated with the same kinetics as normal cells, following DSB induction (data not shown). This indicates that other kinases can fully compensate for the loss of ATM in human cells, but not necessarily in mouse cells. SU11752 inhibited H2AX phosphorylation by 50% at 50 mM, and lower concentrations of the drug had no effect ( Figure 8b ). As expected, wortmannin inhibited H2AX phosphorylation completely, as previously reported (Paull et al., 2000) . Together, these sets of data show that SU11752 does inhibit other protein kinases that recognize the [S/T] Q-motif, but to a lesser degree compared to wortmannin.
SU11752 is a poor inhibitor of ATM kinase acitivity in cells
ATM is a member of the PI3-kinase-related protein kinase family, and it has a central role in DSB signaling (Shiloh, 2001) . ATM is also inhibited by wortmannin at the same concentrations required to inhibit DNA-PK (Banin et al., 1998) . We therefore wanted to know if SU11752 inhibited ATM in cells. ATM kinase activity is required for phosphorylation of threonine 68 in Chk2, since no phosphorylation is observed in ATM-deficient cells (AT-cells) (Figure 9a ) (Ahn et al., 2000; Matusoka et al., 2000) . Cells pretreated with 25 and 50 mM SU11752 showed only a slight reduction in Chk2 phosphorylation following DSB induction by calicheamicin g1 (Figure 9b ). No inhibition of Chk2 phosphorylation was observed at lower SU11752 concentrations. In contrast, wortmannin inhibited Chk2 phosphorylation down to background levels. This indicates that ATM kinase activity was not inhibited by SU11752 at concentrations that resulted in inhibition of DSB repair (12 mM), and that the ATM kinase activity was only slightly affected at concentrations that resulted in radiosensitization (50 mM).
Discussion
In this report, we describe the first step towards development of a selective DNA-PK inhibitor. The initial screen was done with a library of threesubstituted indolin-2-ones, since this class of compounds has been used to produce several selective kinase inhibitors (Sun et al., 1998) . The best candidate was further characterized and found to inhibit DNA-PK with an IC 50 of 0.13 mM by competition with ATP binding. As expected, SU11752 inhibited DSB repair and sensitized cells to radiation, hallmarks of DNA-PK deficiency. This indicated that SU11752 inhibited DNA-PK in cells. Importantly, we also found that SU11752 was a much less efficient inhibitor of the PI3-kinase p110g in vitro, and it did not affect cell cycle progression at concentrations that inhibited DSB repair. Previously characterized DNA-PK inhibitors were initially identified as PI3-kinase inhibitors that also show some activity to DNA-PK and ATM due to structural similarities in the kinase domains (Chernikova et al., 1999; Burma et al., 2002) . These inhibitors, exemplified by wortmannin, inhibit DNA-PK and ATM at 100-fold higher concentrations than required to observe the inhibition of PI3-kinases and effects on cell cycle progression. The fact that SU11752 was a poor inhibitor of the PI3-kinase p110g puts SU11752 in a unique class of compounds showing improved selectivity against DNA-PK. We have also provided evidence that SU11752 is not a general inhibitor of PI3-kinase-related kinases. SU11752 was unable to inhibit ATM kinase activity in cells at concentrations that result in inhibition of DSB repair. Furthermore, phosphorylation of a collection of ATM and ATR targets containing the [S/T]Q-motif was only partially inhibited by SU11752 at the highest concentration tested. In contrast, wortmannin was able to completely eliminate these phosphorylation events. We believe our results demonstrate that SU11752 is an excellent starting point for the development of specific DNA-PK inhibitors. At the present stage, however, SU11752 is unlikely to be clinically useful due to its relatively weak binding to DNA-PK.
Another compound, OK-1035, was initially reported to inhibit DNA-PK with an IC 50 of 8 mM (Take et al., 1995) and affect p53 activity in cells following DNA damage (Take et al., 1996) . No information concerning effects on PI3-kinase activity or DSB repair was reported. However, a recent study showed that OK-1035 is a poor inhibitor of DNA-PK with a IC 50 of over 100 mM, and therefore puts doubt on the previous reports concerning this drug (Stockley et al., 2001) .
Several reports now show that overexpression of DNA-PK in tumor cells results in resistance to cancer treatment (Shen et al., 1997; Frit et al., 1999; Sirzen et al., 1999; Vaganay-Juery et al., 2000; Zhao et al., 2000; Xu et al., 2002) . In addition, cancer cells initially resistant to chlorambucil or nitrogen mustard can be rendered sensitive to these agents when combined with wortmannin Muller et al., 1998) . It is therefore possible that a selective DNA-PK inhibitor will allow treatment of tumors that are otherwise resistant to radiotherapy and anticancer drugs. The notion that mice (Gao et al., 1998) and horses (Wiler et al., 1995; Shin et al., 1997) lacking DNA-PKcs have little apparent defects other than immunodeficiency and ionizing radiation sensitivity indicates that a specific DNA-PK inhibitor can be well tolerated in the absence of radiation. This will likely facilitate the evaluation of this class of drugs in combination with the existing cancer therapy. Our data indicate that SU11752 is a good starting point to develop more specific inhibitors to DNA-PK that can be used in combination with radiotherapy to improve tumor control.
Materials and methods

Cells and reagents
SU11752 was dissolved in DMSO at 20 mg/ml and stored at À701C. Calicheamicin g1 was a generous gift from George Ellestad (Wyeth-Ayers Research). The drug was dissolved at 2 mM in DMSO and stored at À701C. Wortmannin (Sigma) was dissolved at 1 mg/ml in DMSO and stored at À701C. Recombinant human p110g was purchased from Alexis. The glioblastoma cell line M059K and primary human fibroblasts were grown in Dulbeccos MEM with glutamax (Invitrogen) supplemented with 10% fetal calf serum, streptomycin and penicillin. Epstein-Barr virus immortalized normal (GM02254) and A-T (GM01526) human lymphoblast cultures were obtained from Coriell Institute for Medical Research. All lymphoblast cells were grown in RPMI-1640 medium (Invitrogen) supplemented with 10% fetal bovine serum, 100 nM glutamine and penicillin/streptomycin in a humidified atmosphere with 5% CO 2 . FACS analysis of cell cycle distribution after propidium iodide staining was done using standard protocols. Monolayers were irradiated on ice using a Philips RT 100 X-ray machine. An acceleration voltage of 70 kV was used.
DNA-PK assay
DNA-PKcs and Ku were purified from human placenta, as previously described (Ma˚rtensson and Hammarsten, 2002) . DNA-PK kinase activity was measured by mixing 20-30 ng Ku, 3 ng DNA-PKcs with 0.5 mg/ml substrate peptide (EPPLSQEAFADLWKK) in a total volume of 10 ml DNA-PK kinase buffer (10 mM Tris-HCl, pH 7.5, 0.1 mM EDTA, 50 mM NaCl, 20 mM MgCl 2 , 10 mM 2-mercaptoethanol, 62 mM ATP and 16 nM [ 32 P] ATP 5000 Ci/mmol (Amersham Pharmacia) and 20 ng of linear plasmid DNA (pBluescript KS þ II linearized with SmaI). Inhibitors were diluted in PBS and added last. The DNA-PK assay was performed with a fixed concentration of SU11752 (0, 0.5, 1, 2 and 4 mM) and various concentrations of cold ATP. The amount of [ 32 P] ATP was kept constant at 16 nM. All solutions and reaction mixtures were kept on ice during preparation of the samples. The samples were incubated at 371C for 12 min and then transferred back to ice. Reactions were acidified by adding 10 ml of 50% acetic acid and then transferred to phosphocellulose filters (Whatman P81). Filters were washed twice in 250 ml of 15% acetic acid. Radioactivity bound to the filters was measured by scintillation counting. Samples with no added enzyme were used to determine the background that was subtracted from each value.
Wortmannin binding assay
First, 0.1 mg of DNA-PKcs was mixed with SU11752, ATP or ADP, as indicated in Figure 3 , in a total of 10 ml of assay buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA, 10 mM MgCl 2 ). After incubation for 10 min on ice, wortmannin was added to a final concentration of 0.6 mM and the mixture incubated for another 10 min on ice. The reaction was spotted on Hybond-C extra membrane (Amersham Bioscience) and the membrane was blocked with blocking buffer (TBS, 5% gelatin, 1 mg/ml BSA, 0.1% Tween-20). After washing, the membrane was incubated with the wortmannin antibody (supplied by Matthias Wymann) diluted 1 : 1000 in blocking buffer. After incubation with a horseradish peroxidase secondary antibody diluted 1 : 1000 in blocking solution, the membrane was developed with ECL (Amersham Bioscience), according to the manufacturer's instructions. The ECL signal was quantified using a digital camera-based system (Chemidoc, Biorad).
P110g kinase assay
Micelles containing phosphatidylinositol were prepared prior to each experiment, by mixing 1 mg of phosphatidylinositol with 40 mg phosphatidylserine in 300 ml chloroform, and the resulting solution dried under nitrogen gas. The dried lipids were resuspended in 100 ml 25 mM HEPES pH 7.5 containing 1 mM EGTA by sonication. The kinase reaction was performed by mixing 2 ng of recombinant p110g with 5 ml of micelles in 20 ml DNA-PK kinase buffer, supplemented with the inhibitors indicated in Figure 4 and incubated at 371C for 30 min. The reaction was stopped on ice and acidified by addition of 100 ml of 1 M HCl, and lipids were extracted with 300 ml of methanol : chloroform (1 : 1). The radioactivity in the methanol : chloroform phase was measured by liquid scintillation. Samples with no added p110g were used to determine the background that was typically 100-fold below the maximal activity. Relative kinase activity was calculated on background-subtracted values.
Measurement of DSB repair
The DSB analysis was performed essentially as described (Elmroth et al., 2000) , except for the lysis protocol. Briefly, the monolayers were rinsed with ice-cold PBS after exposure to drugs or X-rays, and cells were scraped off. The cell suspension was mixed with agarose and transferred to a plug mold. The cells in the gel-plug were lysed on ice for 24 h in freshly made 1% sodium dodecyl sulfate and 1 mg/ml proteinase K in 10 mM EDTA pH 8.2. The gel-plugs were molded into 0.7% agarose gels and run in 1 Â TAE at þ 51C for 17 h, using constant field gel electrophoresis. The gels were stained with ethidium bromide and analysed by a fluorescence scanner (Typhoon, Amersham Pharmacia) and the fraction of DNA entering the gel (FAR) was quantified using the Image Quant software.
H2AX, [S/T]Q and Chk2 phosphorylation
H2AX phosphorylation was measured in cells preincubated or not preincubated with the inhibitors indicated in Figure 8 for 1 h at 371C, before addition of calicheamicin g1 (10 nM) for 45 min to allow induction of DSB. After washing with cold PBS, cells were scraped off the plates and H2AX phosphorylation measured as described (Elmroth et al., 2003) . Chk2 or [S/T]Q phosphorylation was measured in human lymphoblast cells pretreated for 1 h with the indicated drugs. Cells were lysed in 20 mM Tris Á HCl buffer (pH 8.0) containing 100 mM NaCl, 0.5% Triton X-100, 10 mM NaF, 1 mM Na 3 VO 4 , 2 mg/ml aprotinin, 2 mg/ml leupeptin, 2 mg/ml antipain and 1 mM phenylmethylsulfonyl fluoride (PMSF) for 15 min on ice. The cell extract was clarified by centrifugation at 12 000 r.p.m. for 10 min at 41C, and separated on 10% SDS-PAGE. After transfer to nitrocellulose membrane (Amersham Biosciences), the membrane was blocked with blotto and incubated with a polyclonal antibody specific for Chk2 phosphorylated at Thr68 (Cell Signaling Technology) or an rabbit antiphospho-[S/T]Q antibody (Cell Signaling Technology). After incubation with secondary antibody, the membrane was developed with enhanced chemoluminescence (Dura ECL) (Pierce). After stripping off the membranes with 50 mM glycine pH 2.3 for 30 min, the membranes were blocked and reprobed with a Ku70 antibody (Novagene) to show equal loading.
Abbreviations DSB, DNA double-stranded break; DNA-PK, DNA-dependent protein kinase; DNA-PKcs, the catalytic subunit of DNA-PK; ssDNA, single-stranded DNA; dsDNA, doublestranded DNA; PI3-kinase, phosphatidylinositol-3 kinase; ATM, ataxia telangiectasia mutated; ATR, ATM and rad3-related; PBS, phosphate-buffered saline; TBS, Tris-buffered saline.
